ArticlePLoS pathogens2022
Recombinant Lloviu virus as a tool to study viral replication and host responses.
Article in PLoS pathogens, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 28 citations in OpenAlex.
- De novo recovery of Ghana virus, an African bat Henipavirus, reveals differential tropism and attenuated pathogenicity compared to Nipah virus.Cell reports · 2026Article
- Harnessing Hazara Virus as a Surrogate for Crimean-Congo Hemorrhagic Fever Virus Enables Inactivation Studies at a Low Biosafety Level.Pathogens (Basel, Switzerland) · 2025Article
- Marburg Virus Minigenome Assays.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Studying bats using a One Health lens: bridging the gap between bat virology and disease ecology.Journal of virology · 2024Review
- A high-throughput, polymerase-targeted RT-PCR for broad detection of mammalian filoviruses.Microbiology spectrum · 2024Article
- Review
- A Comparative Assessment of the Pathogenic Potential of Newly Discovered Henipaviruses.Pathogens (Basel, Switzerland) · 2024Review
- Article
- Heat Inactivation of Nipah Virus for Downstream Single-Cell RNA Sequencing Does Not Interfere with Sample Quality.Pathogens (Basel, Switzerland) · 2024Article
- Metagenomic Sequencing of Lloviu Virus from Dead Schreiber's Bats in Bosnia and Herzegovina.Microorganisms · 2023Article
- Recent advances in lung organoid development and applications in disease modeling.The Journal of clinical investigation · 2023Review
- Pathogenicity of Lloviu and Bombali Viruses in Type I Interferon Receptor Knockout Mice.The Journal of infectious diseases · 2023Article
- Art of the Kill: Designing and Testing Viral Inactivation Procedures for Highly Pathogenic Negative Sense RNA Viruses.Pathogens (Basel, Switzerland) · 2023Article
- Isolation and genome characterization of Lloviu virus from Italian Schreibers's bats.Scientific reports · 2023Article
- Establishment of an Inactivation Method for Ebola Virus and SARS-CoV-2 Suitable for Downstream Sequencing of Low Cell Numbers.Pathogens (Basel, Switzerland) · 2023Article
- Labeling Ebola Virus with a Self-Splicing Fluorescent Reporter.Microorganisms · 2022Article
- Ebola virus infection induces a delayed type I IFN response in bystander cells and the shutdown of key liver genes in human iPSC-derived hepatocytes.Stem cell reports · 2022Article
- Correction: Recombinant Lloviu virus as a tool to study viral replication and host responses.PLoS pathogens · 2022Article
- Isolation of infectious Lloviu virus from Schreiber's bats in Hungary.Nature communications · 2022Article
Corrections and comments
- Erratum issued
Authors and funding
25 authors at 4 institutions in 4 countries.
Funding
Abstract
Next generation sequencing has revealed the presence of numerous RNA viruses in animal reservoir hosts, including many closely related to known human pathogens. Despite their zoonotic potential, most of these viruses remain understudied due to not yet being cultured. While reverse genetic systems can facilitate virus rescue, this is often hindered by missing viral genome ends. A prime example is Lloviu virus (LLOV), an uncultured filovirus that is closely related to the highly pathogenic Ebola virus. Using minigenome systems, we complemented the missing LLOV genomic ends and identified cis-acting elements required for LLOV replication that were lacking in the published sequence. We leveraged these data to generate recombinant full-length LLOV clones and rescue infectious virus. Similar to other filoviruses, recombinant LLOV (rLLOV) forms filamentous virions and induces the formation of characteristic inclusions in the cytoplasm of the infected cells, as shown by electron microscopy. Known target cells of Ebola virus, including macrophages and hepatocytes, are permissive to rLLOV infection, suggesting that humans could be potential hosts. However, inflammatory responses in human macrophages, a hallmark of Ebola virus disease, are not induced by rLLOV. Additional tropism testing identified pneumocytes as capable of robust rLLOV and Ebola virus infection. We also used rLLOV to test antivirals targeting multiple facets of the replication cycle. Rescue of uncultured viruses of pathogenic concern represents a valuable tool in our arsenal for pandemic preparedness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.